JP2006508912A - 非小胞性カチオン脂質調製物 - Google Patents

非小胞性カチオン脂質調製物 Download PDF

Info

Publication number
JP2006508912A
JP2006508912A JP2004530254A JP2004530254A JP2006508912A JP 2006508912 A JP2006508912 A JP 2006508912A JP 2004530254 A JP2004530254 A JP 2004530254A JP 2004530254 A JP2004530254 A JP 2004530254A JP 2006508912 A JP2006508912 A JP 2006508912A
Authority
JP
Japan
Prior art keywords
preparation
mol
concentration
amphiphile
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004530254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508912A5 (cg-RX-API-DMAC7.html
Inventor
ハース ハンリッヒ
ペイマン トラルフ
ファットラー ウアズラ
Original Assignee
メディゲーネ オンコロギー ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02018907A external-priority patent/EP1393719A1/en
Application filed by メディゲーネ オンコロギー ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical メディゲーネ オンコロギー ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2006508912A publication Critical patent/JP2006508912A/ja
Publication of JP2006508912A5 publication Critical patent/JP2006508912A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
JP2004530254A 2002-08-23 2003-08-25 非小胞性カチオン脂質調製物 Pending JP2006508912A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02018907A EP1393719A1 (en) 2002-08-23 2002-08-23 Camptothecin-carboxylate formulations
PCT/EP2003/006760 WO2004002454A1 (en) 2002-06-26 2003-06-26 Camptothecin-carboxylate formulations
PCT/EP2003/009398 WO2004017943A2 (en) 2002-08-23 2003-08-25 Non-vesicular cationic lipid formulations

Publications (2)

Publication Number Publication Date
JP2006508912A true JP2006508912A (ja) 2006-03-16
JP2006508912A5 JP2006508912A5 (cg-RX-API-DMAC7.html) 2006-10-05

Family

ID=31947818

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004530254A Pending JP2006508912A (ja) 2002-08-23 2003-08-25 非小胞性カチオン脂質調製物

Country Status (6)

Country Link
US (1) US20050232984A1 (cg-RX-API-DMAC7.html)
EP (1) EP1530456A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006508912A (cg-RX-API-DMAC7.html)
AU (1) AU2003270102B2 (cg-RX-API-DMAC7.html)
CA (1) CA2495913A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004017943A2 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2012157721A1 (ja) * 2011-05-17 2014-07-31 三菱瓦斯化学株式会社 ピロロキノリンキノンと糖を含むリポソーム
JP2015535292A (ja) * 2012-11-05 2015-12-10 サーモディクス，インコーポレイテッド 疎水性生理活性物質を送達するための組成物および方法
JP2018512442A (ja) * 2015-04-13 2018-05-17 ファウンテン テクノロジーズ インターナショナル，エルエルシー 超微細脂質構造体の作製のためのワンステップ法
US10213528B2 (en) 2011-05-20 2019-02-26 Surmodics, Inc. Delivery of hydrophobic active agent particles
US12226552B2 (en) 2019-09-30 2025-02-18 Surmodics, Inc. Active agent depots formed in situ

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
KR101173510B1 (ko) 2002-08-23 2012-08-21 슬로안-케테링인스티튜트퍼캔서리서치 에포틸론, 이의 중간물질과 유사체의 합성 및 이들의 용도
JP2010505883A (ja) 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
MX2011003207A (es) * 2008-09-27 2011-11-04 Jina Pharmaceuticals Inc Preparaciones farmaceuticas a base de lipidos para la aplicacion oral y topica; sus composiciones, metodos y usos.
US10058634B2 (en) 2009-04-28 2018-08-28 Surmodics, Inc. Devices and methods for delivery of bioactive agents
CA2816529A1 (en) 2010-11-01 2012-05-10 University Of Technology, Sydney Immune-modulating agents and uses therefor
US10213529B2 (en) 2011-05-20 2019-02-26 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
US11246963B2 (en) 2012-11-05 2022-02-15 Surmodics, Inc. Compositions and methods for delivery of hydrophobic active agents
US10220095B2 (en) 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
WO2015179918A1 (en) 2014-05-27 2015-12-03 The University Of Queensland Modulation of cellular stress
HUE054894T2 (hu) 2014-11-05 2021-10-28 Selecta Biosciences Inc Rapamicint stabil, túltelített állapotban tartalmazó szintetikus nanohordozókkal kapcsolatos módszerek és készítmények
US10898446B2 (en) 2016-12-20 2021-01-26 Surmodics, Inc. Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces
US20210308058A1 (en) 2020-03-11 2021-10-07 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6144808A (ja) * 1984-03-08 1986-03-04 フアレス　フアーマスーチカル　リサーチ　エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
WO2001072264A2 (de) * 2000-03-28 2001-10-04 Cognis Iberia, S.L. Pro-liposomal verkapselte zubereitungen (iv)
WO2001074302A1 (de) * 2000-03-28 2001-10-11 Cognis Iberia, S.L. Pro-liposomal verkapselte zubereitungen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4830858A (en) * 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
DE4430593C2 (de) * 1994-08-20 1999-01-14 Max Delbrueck Centrum Verfahren zur Herstellung von Liposomal verkapseltem Taxol
US5834012A (en) * 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US5753262A (en) * 1995-06-07 1998-05-19 Aronex Pharmaceuticals, Inc. Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US20030072794A1 (en) * 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
AU2001275423B2 (en) * 2000-06-09 2007-01-11 Regulon, Inc. Encapsulation of polynucleotides and drugs into targeted liposomes
JP4536235B2 (ja) * 2000-09-18 2010-09-01 本田技研工業株式会社 ハイドロゲル

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6144808A (ja) * 1984-03-08 1986-03-04 フアレス　フアーマスーチカル　リサーチ　エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
WO2001072264A2 (de) * 2000-03-28 2001-10-04 Cognis Iberia, S.L. Pro-liposomal verkapselte zubereitungen (iv)
WO2001074302A1 (de) * 2000-03-28 2001-10-11 Cognis Iberia, S.L. Pro-liposomal verkapselte zubereitungen

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2012157721A1 (ja) * 2011-05-17 2014-07-31 三菱瓦斯化学株式会社 ピロロキノリンキノンと糖を含むリポソーム
US10213528B2 (en) 2011-05-20 2019-02-26 Surmodics, Inc. Delivery of hydrophobic active agent particles
US11529440B2 (en) 2011-05-20 2022-12-20 Surmodics, Inc. Delivery of hydrophobic active agent particles
US12083249B2 (en) 2011-05-20 2024-09-10 Surmodics, Inc. Delivery of hydrophobic active agent particles
JP2015535292A (ja) * 2012-11-05 2015-12-10 サーモディクス，インコーポレイテッド 疎水性生理活性物質を送達するための組成物および方法
JP2018512442A (ja) * 2015-04-13 2018-05-17 ファウンテン テクノロジーズ インターナショナル，エルエルシー 超微細脂質構造体の作製のためのワンステップ法
US12226552B2 (en) 2019-09-30 2025-02-18 Surmodics, Inc. Active agent depots formed in situ

Also Published As

Publication number Publication date
WO2004017943A2 (en) 2004-03-04
EP1530456A2 (en) 2005-05-18
US20050232984A1 (en) 2005-10-20
WO2004017943A3 (en) 2004-05-13
AU2003270102B2 (en) 2008-10-02
AU2003270102A1 (en) 2004-03-11
CA2495913A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
CN103002876B (zh) 亲脂性化合物的改进脂质体制剂
AU2003270102B2 (en) Non-vesicular cationic lipid formulations
US9655848B2 (en) Liposomes for in-vivo delivery
US20100178243A1 (en) Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
JP4885715B2 (ja) イリノテカン製剤
EP1553923B1 (en) Camptothecin-carboxylate formulations
US20110190623A1 (en) Thermally-activatable liposome compositions and methods for imaging, diagnosis and therapy
AU2003249882A2 (en) Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
EP1547580A1 (en) Loading of a camptothecin drug into colloidal nanoparticles
EP1547582A1 (en) Method of producing lipid complexed camptothecin-carboxylate
JP2007262026A (ja) リポソームの製造方法
EP1374864A1 (en) Amphiphilic taxane compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060817

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20070706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100310

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100903